These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31428320)

  • 1. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups.
    Miarons M; Sánchez-Ulayar A; Sempere G; Marín S; Castellví JM
    Eur J Hosp Pharm; 2019 May; 26(3):135-139. PubMed ID: 31428320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
    Masip M; Tuneu L; Pagès N; Torras X; Gallego A; Guardiola JM; Faus MJ; Mangues MA
    Int J Clin Pharm; 2015 Dec; 37(6):1143-51. PubMed ID: 26267215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric treatment considerations with direct acting antivirals in hepatitis C.
    Sockalingam S; Tseng A; Giguere P; Wong D
    BMC Gastroenterol; 2013 May; 13():86. PubMed ID: 23672254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.
    Sundberg I; Lannergård A; Ramklint M; Cunningham JL
    BMC Psychiatry; 2018 May; 18(1):157. PubMed ID: 29843679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
    Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
    Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
    Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review.
    Quelhas R; Lopes A
    J Psychiatr Pract; 2009 Jul; 15(4):262-81. PubMed ID: 19625882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis.
    Yamamoto H; Ikesue H; Ikemura M; Miura R; Fujita K; Chung H; Suginoshita Y; Inokuma T; Hashida T
    J Pharm Health Care Sci; 2018; 4():17. PubMed ID: 30026959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.
    Raza MN; Sughra K; Zeeshan N; Anwar MZ; Shahzad MA; Rashid U; Afroz A; Munir H
    Braz J Biol; 2021; 83():e252610. PubMed ID: 34909837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
    Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
    Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less.
    Souliotis K; Siakavellas S; Golna C; Manesis E; Papatheodoridis G; Hatzakis A
    Hippokratia; 2018; 22(3):127-131. PubMed ID: 31641333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Direct-Acting Antiviral Treatment of Psychiatric Patients with Comorbid Hepatitis C Virus Infection.
    Gayam V; Jegede O; Tiongson B; Mandal AK; Sidhu J; Garlapati P
    Dig Dis; 2020; 38(3):232-239. PubMed ID: 31494648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients.
    El Kassas M; El Sheemy R; Alboraie M; El Badry M; Wifi MN; Youssef N; Ezzat S; Tahoon M; Abdelsalam L; Abdelhakam SM; Ali-Eldin Z
    Eur Geriatr Med; 2019 Apr; 10(2):295-302. PubMed ID: 34652758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals.
    Syed T; Fazili J; Ali IA; Zhao D; Hughes D; Mahmood S
    Cureus; 2018 Jun; 10(6):e2843. PubMed ID: 30280052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients.
    Quereda C; Corral I; Moreno A; Pérez-Elías MJ; Casado JL; Dronda F; Rodríguez-Sagrado MA; Hernández B; Moreno S
    J Acquir Immune Defic Syndr; 2008 Sep; 49(1):61-3. PubMed ID: 18667933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.